KRAS Testing and Its Importance in Colorectal Cancer

被引:0
作者
Deepa T. Patil
Cory R. Fraser
Thomas P. Plesec
机构
[1] Cleveland Clinic,Department of Anatomic Pathology
来源
Current Oncology Reports | 2010年 / 12卷
关键词
KRAS; Mutation; Colorectal cancer; Codon 12; Codon 13; Cetuximab; Panitumumab;
D O I
暂无
中图分类号
学科分类号
摘要
Cetuximab and panitumumab are monoclonal antibodies used in the treatment of metastatic colorectal cancer (mCRC) by selectively targeting the epidermal growth factor receptor (EGFR) axis. Studies have shown that mutations in codons 12/13 of exon 2 of the KRAS gene render these therapies ineffective. As a result, the National Comprehensive Cancer Network and American Society of Clinical Oncology recommend KRAS mutation testing in mCRC. Appropriate testing depends on the coordinated efforts of the entire treatment team, including the pathologist, who selects the tumor sample and testing platform as well as interprets and reports results. In addition to describing rationale and methodologies for KRAS mutation testing, the authors also summarize their algorithmic approach and elaborate the potential role of newer molecular biomarkers to predict anti-EGFR resistance in wild-type KRAS tumors.
引用
收藏
页码:160 / 167
页数:7
相关论文
共 130 条
  • [1] Jemal A(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-249
  • [2] Siegel R(2008)Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy Pharmacotherapy 28 18S-22S
  • [3] Ward E(2002)Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 1S-13S
  • [4] Engstrom PF(2003)An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 12 541-552
  • [5] Mendelsohn J(2005)Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann Oncol 16 189-194
  • [6] Burgess AW(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
  • [7] Cho HS(2005)The epidermal growth factor receptor as a target for colorectal cancer therapy Semin Oncol 32 52-60
  • [8] Eigenbrot C(2001)Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer 92 1331-1346
  • [9] Spano JP(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-1174
  • [10] Fagard R(2006)Recurrent KRAS codon 146 mutations in human colorectal cancer Cancer Biol Ther 5 928-932